DYNAVAX ESTABLISHES COLLABORATION FOR TLR-9 AGONISTS FOR ASTHMA AND COPD WITH ASTRAZENECA

Dynavax Technologies Corporation has entered into a research collaboration and license agreement with AstraZeneca for the discovery and development of TLR-9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The collaboration will utilize Dynavax's proprietary second-generation TLR-9 agonist immunostimulatory sequences or ISS. Drug Newswire (http://www.drugnewswire.com/5588/)